Literature DB >> 24277726

Timing of xenon-induced delayed postconditioning to protect against spinal cord ischaemia-reperfusion injury in rats.

Y W Yang1, W P Cheng2, J K Lu1, X H Dong1, C B Wang1, J Zhang1, L Y Zhao1, Z F Gao1.   

Abstract

BACKGROUND: This study was designed to assess the neuroprotective effect of xenon-induced delayed postconditioning on spinal cord ischaemia-reperfusion injury (IRI) and to determine the time of administration for best neuroprotection in a rat model of spinal cord IRI.
METHODS: Fifty male rats were randomly divided equally into a sham group, control group, and three xenon postconditioning groups (n=10 per group). The control group underwent spinal cord IRI and immediately inhaled 50% nitrogen/50% oxygen for 3 h at the initiation of reperfusion. The three xenon postconditioning groups underwent the same surgical procedure and immediately inhaled 50% xenon/50% oxygen for 3 h at the initiation of reperfusion or 1 and 2 h after reperfusion. The sham operation group underwent the same surgical procedure without aortic occlusion, and inhaled 50% nitrogen/50% oxygen. Neurological function was assessed using the Basso, Beattie, and Bresnahan score at 4, 24, and 48 h of reperfusion. Histological examination was performed using Nissl staining and immunohistochemistry, and apoptosis was detected by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labelling staining.
RESULTS: Compared with the control group, the three xenon postconditioning groups showed improvements in neurological outcomes, and had more morphologically normal neurones at 48 h of reperfusion. Apoptotic cell death was reduced and the ratio of Bcl-2/Bax immunoreactivity increased in xenon-treated rats compared with controls.
CONCLUSIONS: Xenon postconditioning up to 2 h after reperfusion provided protection against spinal cord IRI in rats, but the greatest neuroprotection occurred with administration of xenon for 1 h at reperfusion.
© The Author [2013]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  neuroprotectant; spinal cord, ischaemia–reperfusion injury; xenon, delayed postconditioning

Mesh:

Substances:

Year:  2013        PMID: 24277726     DOI: 10.1093/bja/aet352

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  6 in total

Review 1.  [Neuroprotection by noble gases: New developments and insights].

Authors:  A V Fahlenkamp; R Rossaint; M Coburn
Journal:  Anaesthesist       Date:  2015-11       Impact factor: 1.041

Review 2.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

3.  [Xenon post-conditioning protects against spinal cord ischemia-reperfusion injury in rats by downregulating mTOR pathway and inhibiting endoplasmic reticulum stress-induced neuronal apoptosis].

Authors:  L Luo; J Tong; L Li; M Jin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

4.  Xenon Protects Against Septic Acute Kidney Injury via miR-21 Target Signaling Pathway.

Authors:  Ping Jia; Jie Teng; Jianzhou Zou; Yi Fang; Xie Wu; Mingyu Liang; Xiaoqiang Ding
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

5.  Delayed xenon post-conditioning mitigates spinal cord ischemia/reperfusion injury in rabbits by regulating microglial activation and inflammatory factors.

Authors:  Yan-Wei Yang; Yun-Lu Wang; Jia-Kai Lu; Lei Tian; Mu Jin; Wei-Ping Cheng
Journal:  Neural Regen Res       Date:  2018-03       Impact factor: 5.135

Review 6.  Medical Gas Therapy for Tissue, Organ, and CNS Protection: A Systematic Review of Effects, Mechanisms, and Challenges.

Authors:  Ross D Zafonte; Lei Wang; Christian A Arbelaez; Rachel Dennison; Yang D Teng
Journal:  Adv Sci (Weinh)       Date:  2022-03-04       Impact factor: 17.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.